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The early steps of HIV-1 replication involve the entry of HIV-1 into the nucleus, which is characterized
by viral interactions with nuclear pore components. HIV-1 developed an evolutionary strategy to usurp
the nuclear pore machinery and chromatin in order to integrate and efﬁciently express viral genes.
In the current work, we studied the role of nucleoporins 153 and 98 (Nup153 and Nup98) in infection of
human Jurkat lymphocytes by HIV-1. We showed that Nup153-depleted cells exhibited a defect in
nuclear import, while depletion of Nup 98 caused a slight defect in HIV integration. To explore the
biochemical viral determinants for the requirement of Nup153 and Nup98 during HIV-1 infection, we
tested the ability of these nucleoporins to interact with HIV-1 cores. Our ﬁndings showed that both
nucleoporins bind HIV-1 cores suggesting that this interaction is important for HIV-1 nuclear import
and/or integration. Distribution analysis of integration sites in Nup153-depleted cells revealed a
reduced tendency of HIV-1 to integrate in intragenic sites, which in part could account for the large
infectivity defect observed in Nup153-depleted cells. Our work strongly supports a role for Nup153 in
HIV-1 nuclear import and integration.
& 2013 Elsevier Inc. All rights reserved.Introduction
The inﬂuence of the physiological state of cells on retroviral
replication was initially studied by Rubin and Temin; they
demonstrated that stopping cell division by X-rays or UV light
prevents Rous Sarcoma virus replication (Rubin and Temin, 1959).
Subsequent research established the relationship between cell
cycle stage and retroviral infection, revealing that diverse retro-
viruses have different requirements for productive infection (Katz
et al., 2003; Suzuki and Craigie, 2007; Yamashita and Emerman,
2006). For example, gamma-retroviruses such as murine leuke-
mia virus (MLV) require the host cell to pass through mitosis for
productive infection (Lewis and Emerman, 1994; Roe et al., 1993).
By contrast, lentiviruses such as HIV-1 show no difference in
productive infection when comparing dividing versus non-
dividing cells (Lewis et al., 1992). This evidence suggests thatll rights reserved.
, Institut Pasteur, 25-28 rue
(F. Di Nunzio),
.lentiviruses have developed speciﬁc mechanisms for the infection
of non-dividing cells. The ability of HIV-1 to infect non-dividing
cells has been attributed to the capacity of the virus to transport
the pre-integration complex (PIC) to the nucleus (Miller et al.,
1997; Suzuki and Craigie, 2007). Translocation of the HIV-1 PIC
into the nucleus is not a simple process, as its size is similar to
that of a ribosome, which is at least 56 nm in diameter
(Bowerman et al., 1989; Miller et al., 1997). Because of this large
size, it is unlikely that the PIC enters the nucleus by passive
diffusion (Mattaj and Englmeier, 1998). On the contrary, HIV-1
PIC translocation into the nucleus must be an active process.
Several components of the PIC such as matrix, Vpr, integrase and
the central DNA ﬂap, have been proposed to be directly involved
in PIC transport into the nucleus (De Rijck et al., 2007; Fassati,
2006). Although barely detectable amounts of capsid can be found
on the HIV-1 PIC (Bukrinsky et al., 1993; Fassati and Goff, 2001;
Iordanskiy et al., 2006; Miller et al., 1997), recent evidence has
shown that capsid plays a role in the ability of HIV-1 to infect
non-dividing cells (Yamashita and Emerman, 2004, 2006;
Yamashita et al., 2007). In agreement, several studies found the
HIV-1 core associated to the nuclear pore (Arhel et al., 2007;
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PIC to enter the nucleus is not completely understood, it is
accepted that nuclear import of the complex is active and
energy-dependent (Suzuki and Craigie, 2007).
In addition to the viral determinants involved in HIV-1 PIC
nuclear import, several host factors have been described to play a
role in this process: 1) importin 7 (Ao et al., 2007; Fassati et al.,
2003; Zaitseva et al., 2009), 2) Importin a3 (Ao et al., 2010), 3)
importin a/importin b heterodimer (Fassati et al., 2003; Gallay
et al., 1997; Hearps and Jans, 2006), 4) transportin-SR2/TNPO3
(Brass et al., 2008; Christ et al., 2008; Konig et al., 2008; Krishnan
et al., 2010; Levin et al., 2010; Thys et al., 2011; Valle-Casuso
et al., 2012; Zhou et al., 2008), 5) RANBP2 (Di Nunzio et al., 2012;
Ocwieja et al., 2011) and 6), Nup98 and Nup153 (Di Nunzio et al.,
2012; Konig et al., 2008; Lee et al., 2010; Matreyek and Engelman,
2011; Woodward et al., 2009).
Recent work has suggested a role for Nup98 and Nup153 in
HIV-1 replication (Di Nunzio et al., 2012; Konig et al., 2008;
Matreyek and Engelman, 2011). Nup98, which is symmetrically
localized to the cytoplasmic and nuclear sides of the nuclear pore,
is involved in HIV-1 integration (Di Nunzio et al., 2012; Ebina
et al., 2004; Konig et al., 2008). Nup153 that localizes to the
nuclear side of the nuclear pore, was initially described to be
involved in HIV-1 replication by three independent genome-wide
siRNA screens (Brass et al., 2008; Konig et al., 2008; Zhou et al.,
2008). Although the C terminus domain of Nup153 has been
shown to bind the HIV-1 integrase protein using bacterially
puriﬁed proteins (Woodward et al., 2009), the genetic determi-
nant for the requirement of Nup153 during HIV-1 infection has
been mapped to the capsid protein (Matreyek and Engelman,
2011). In agreement with the latter, HIV-1 bearing mutations on
capsid showed different infection sensitivities to the depletion of
Nup153 (Lee et al., 2010; Matreyek and Engelman, 2011; Schaller
et al., 2011). However, a direct interaction between capsid and
Nup153 has not been shown.
The current work explores the role of Nup98 and Nup153 in
HIV-1 infection. We initially conﬁrmed the involvement of Nup98
and Nup153 in the early steps of HIV-1 infection by testing
infectivity of Nup98 and Nup153 -depleted Jurkat cells. Nup98-
depleted cells modestly block HIV-1 infection during integration.
By contrast, Nup-153-depleted cells preferentially block HIV-1
infection during nuclear import. In agreement with ﬁndings that
showed capsid as the determinant for the requirement of Nup153,
we demonstrated the ability of Nup153 to interact with the HIV-1
core. Because depletion of Nup153 affects nuclear import but
severely diminishes infectivity, we studied the distribution of
HIV-1 integration sites in Nup153-depleted Jurkat cells. Our
ﬁndings revealed that the intragenic/intergenic ratio of integra-
tion sites changes in Nup153-depleted cells.Results
Depletion of NUP98 and Nup153 expression inhibits HIV-1 infection
of human lymphocytes
To test the role of Nup98 and Nup153 in HIV-1 infection, we
ﬁrst silenced the expression of these nucleoporins in human T cell
lymphoblast-like cells (Jurkat) by using lentiviral particles expres-
sing speciﬁc shRNAs. As shown in Fig. 1A, we used a lentiviral
shRNA construct that expresses the green ﬂuorescent protein
(GFP) and contains a deletion on the U3 region, which will
subsequently facilitate the study of integration sites. These
lentiviral vectors carrying shRNA and GFP as internal reporter
gene were tittered on HeLa cells by ﬂow cytometry. After
transduction of Jurkat cells at the indicated multiplicities ofinfection (MOI), expression of Nup98 and Nup153 was monitored
by western blotting 5 and 3 days after transduction, respectively.
As shown in Fig. 1B, the use of lentiviral particles containing the
different shRNAs achieved strong knockdown (KD) of Nup98 and
Nup153 expression. Next, we challenged nucleoporins-depleted
Jurkat cells with a single dose of HIV-1 expressing luciferase (HIV-
1-Luc) as a reporter for infectivity (Fig. 1C). Depletion of Nup98
decreases the infectivity of HIV-1 by two-fold when compare to
control cells suggesting a small role for Nup98 in HIV-1 infection.
Depletion of Nup153 dramatically affected the ability of HIV-1 to
infect Jurkat cells by410 fold (Fig. 1C), which is in agreement
with similar ﬁndings in HeLa cells (Di Nunzio et al., 2012;
Matreyek and Engelman, 2011). Because Matreyek and colleagues
suggested that capsid is the viral determinant for the requirement
of Nup153 on HIV-1 infection (Matreyek and Engelman, 2011), we
tested the ability of the HIV-1 bearing the capsid mutation N74D,
which is a TNPO3-independent mutant (Lee et al., 2010), to infect
Nup98 and Nup153 -depleted cells (Fig. 1C). For this purpose, we
challenged Nup98 and Nup153 -depleted cells with similar
amounts of HIV-1-Luc and HIV-1-N74D-Luc normalized by p24,
as described in the Material and methods section. HIV-1-N74D-
Luc infection of Nup98-depleted cells was not affected when
compared to control cells (Fig. 1C). By contrast, HIV-1–N74D–Luc
infection of Nup153-depleted Jurkat cells was inhibited to a
similar extent when compared to wild type HIV-1(Fig. 1C).
As a control, we infected TNPO3-depleted cells with HIV-1–
N74D–Luc (Fig. S1), which is a TNPO3-independent virus. These
results suggested that Nup98 and more so Nup153 are required
for HIV-1 infection; therefore, we investigated the step of the
HIV-1 life cycle that requires Nup98 and Nup153. Similarly, we
challenged Nup98- and Nup153-depleted Jurkat cells with p24-
normalized HIV-1-Luc and HIV-1-N74D-Luc viruses and measure
the production of two long terminal repeat (2LTR) circles by real-
time PCR 24 h post-infection (Fig. 1D). The measurement of 2LTR
circles is an indirect evidence that the pre-integration complex
(PIC) has been transported to the nucleus (Butler et al., 2001).
After the viral DNA is imported into the nucleus, it integrates into
the genome; however, a small fraction of this viral DNA is ligated
to produce circular forms by nuclear DNA ligases (Li et al., 2001);
these products are known as 2LTR circles, and they are used as an
indirect measure of nuclear import. Although the 2LTR is an
indirect measure of PIC nuclear import, this methodology is
widely used as a marker of nuclear import (Butler et al., 2001;
Di Nunzio et al., 2012; Ebina et al., 2004; Konig et al., 2008; Lee
et al., 2010; Matreyek and Engelman, 2011; Valle-Casuso et al.,
2012). Depletion of Nup98 did not affect HIV-1–Luc and HIV-1–
N74D–Luc production of 2LTR circles during infection, suggesting
that Nup98 is not likely to be involved in nuclear import of the
PIC. By contrast, HIV-1–Luc production of 2LTR circles during
infection of Nup153-depleted cells was reduced indicating that
Nup153 might be involved in the nuclear import of HIV-1. In
agreement, infection of Nup153-depleted Jurkat cells by HIV-1–
N74D–Luc also rendered a reduction in the production of 2LTR
circles.
To assess the integration of HIV-1 viral DNA into the host
chromatin, we challenged Nup98 and Nup153 -depleted Jurkat
cells with p24-normalized viruses and measure integration by
Alu–PCR at 48 h post-infection (Fig. 1E). We observed a reduction
of integrated HIV-1 proviruses in Nup98-depleted cells when
compared to infection of control cells. However, infection of
Nup98-depleted cells by HIV-1-N74D-Luc viruses showed pro-
viral integration levels similar to control cells consistent with our
infection assays (Fig. 1E). Infection of Nup153-depleted cells by
HIV-1–Luc rendered a larger reduction of proviral integration
when compared to control cells, which is in agreement with the
strong block observed for nuclear import (Fig. 1E). In addition, we
Fig. 1. Depletion of Nup98 and Nup153 expression affects the early steps of HIV-1 replication. To knockdown the expression of Nup98 and Nup153 in Jurkat cells, we used the
pTrip.GFP.H1shRNA vector (A). This vector contains a deletion on the U3 region (DU3) and encodes the green ﬂuorescent protein (GFP) under the control of the CMV promoter to
monitor transduction. shRNA cassettes are inserted in the 30 end of the U3 region, and are regulated by the H1 promoter of the RNA polymerase III, which drives the endogenous
production of shRNA. Viral particles produced using the pTrip.GFP.H1shRNA vector containing the speciﬁc shRNA against Nup98 and Nup153 were used to transduce Jurkat cells at
the indicated multiplicity of infection (MOI). Control cells were transduced with the empty pTrip.GFP.H1shRNA vector. The efﬁciency of the KD was monitored by western blotting
using antibodies against the endogenous Nup98 and Nup153 proteins (B). As a loading control, samples were also blotted using antibodies against b-actin. Nup98 and Nup153 -
depleted cells were challenged with HIV-1 and HIV-1-N74D containing luciferase as a reporter of infection. Viruses were normalized by p24 as described in the Materials and
methods section. Infectivity was determined 48 h post-infection (hpi) by measuring luciferase activity normalized to the amount of protein (C). Infections using the same viruses
were performed to measure the production of 2LTR circles. For this purpose, 24 h pi total genomic DNA from infected cells was used to measure 2LTR circles by real-time PCR
normalized to actin. The percentage of 2LTR circles respect to the control is shown (D). Infections carried out in the presence of Nevirapine 5 mM led to undetectable levels of both
2-LTR circles. Similarly, 24 h pi total genomic DNAwas used to determine proviral integration sites by Alu–PCR, as described in the Materials andmethods section. The percentage of
proviruses respect to control is shown (E). To correlate the expression levels of Nup98 or Nup153 with HIV-1 infectivity, we challenged cells expressing different amounts of NUp98
or Nup153with HIV-1 containing luciferase as a reporter of infection (F, G). Infectivity was determined 48 h post-infection bymeasuring luciferase activity normalized to the amount
of protein. Jurkat cells expressing different amounts of Nup98 or Nup153 were prepared by using viral particles containing the speciﬁc shRNA against Nup98 or Nup153 at different
multiplicities of infection (MOI). The expression levels of Nup98 and Nup153 were measured by Western blotting using antibodies against Nup98 or Nup153. As a loading control,
samples were also blotted using antibodies against b-actin.
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Fig. 2. Correlation between proviral integration and infectivity during HIV-1
infection of Nup98 and Nup153 -depleted cells. Percentages for proviral integra-
tion and infectivity were obtained from Fig. 1C and E and used to calculate the
linear correlation. The Spearman rank correlation coefﬁcient, rs, is 0.8976 and P
value of o0.0001.
Fig. 3. HIV-1 integrase does not interact with Nup98 and Nup153. (A) To test the
ability of GFP-Nup98 to interact with HIV-1 integrase, we co-transfected GFP-
Nup98 together with FLAG-tagged HIV-1 integrase in human 293T cells (INPUT).
Immunoprecipitation of HIV-1 integrase was performed using anti-FLAG anti-
bodies in the presence of 200 mM NaCl, as described in Materials and methods
section. Only the Eluted samples were analyzed for the presence of Nup98 and
HIV-1 integrase by western blotting using anti-GFP and anti-FLAG antibodies,
respectively. (B) Similarly, we tested the ability of Nup153 to interact with HIV-1
integrase at the indicated NaCl concentrations. (C) As a positive control we
assayed the known ability of HIV-1 integrase to interact with LEDGF/p75.
Experiments were performed in triplicates and a representative experiment is
shown. WB, Western blot; IP, Immunoprecipitation.
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dency for Nup153 (Fig. 1E).
Next we tested whether a correlation exists between expression
levels of Nup98 or Nup153 with HIV-1 infectivity (Fig. 1F and G). To
obtain cells expressing different amounts of Nup98 or Nup153, we
transduced Jurkat cells with viral particles containing the speciﬁc
shRNA at the indicated multiplicities of infection. After three days of
transduction, cells were used to measure expression levels of the
Nups and infectivity by an HIV-1-Luc virus (Fig. 1F and G). As shown
In Fig. 1F and G, our results correlated the expression levels of the
nucleoporins with HIV-1 infectivity. This correlation showed that
HIV-1 infection depends upon expression of Nup98 and Nup153.
Overall these studies suggested that the infectivity phenotype
observed for Nup98-depleted cells is due to a contribution of Nup98
to HIV-1 integration (Fig. 2). Regarding Nup153, this work sug-
gested that the infectivity phenotype observed in Nup153-depleted
cells is due to a major contribution of Nup153 to HIV-1 nuclear
import combined to an additional defect in integration (Fig. 2).
Role of integrase in the HIV-1 infectivity phenotype observed for
Nup98 and Nup153 -depleted cells
Infection of Nup98-depleted cells suggested a role for Nup98 in
HIV-1 infection after nuclear import but prior to integration. This
suggested the possibility that Nup98 interacts with HIV-1 inte-
grase. To test the ability of Nup98 to interact with HIV-1 integrase,
we performed co-immunoprecipitation experiments with proteins
expressed in mammalian cells (Fig. 3A), as previously described
(Diaz-Griffero, 2012; Valle-Casuso et al., 2012). In agreement with
previous ﬁndings, Nup98 did not interact with HIV-1 integrase (Ao
et al., 2012). As positive control, we assayed the ability of LEDGF/
p75 to interact with HIV-1 integrase using similar salt concentra-
tions (Fig. 3C). These results suggested that Nup98 is not assisting
HIV-1 replication through an interaction with integrase.
Next we explored the ability of Nup153 to interact with HIV-1
integrase. Contrary to previous ﬁndings (Woodward et al., 2009), we
found that GFP-Nup153 and HIV-1 integrase expressed in human
293T cells did not interact with each other at the indicated salt
concentrations (Fig. 3B). These results suggested that Nup153
expressed in human cells does not interact with HIV-1 integrase.
We believe that the difference between our results and previous
observations is based on the system used to analyze the interaction.
Contrary to us, Woodward and colleagues used bacterially puriﬁed
protein to demonstrate the interaction, and they only tested a
C-terminal fragment of Nup153 (896–1475) (Woodward et al.,
2009).Nup98 and Nup153 interact with HIV-1 in vitro assembled
HIV-1 CA–NC complexes
Genetic experiments suggested that HIV-1 capsid is the viral
determinant for the requirement of Nup153 during HIV-1 infec-
tion (Matreyek and Engelman, 2011). To test this hypothesis
biochemically, we measured the ability of Nup98 and Nup153
to interact with in vitro assembled HIV-1 capsid–nucleocapsid
(CA–NC) complexes as previously described (Ganser et al., 1999;
Lienlaf et al., 2011; Valle-Casuso et al., 2012). The fusion construct
Fig. 4. Binding of GFP-Nup98 proteins to in vitro assembled HIV-1 capsid-
nucleocapsid (CA–NC) complexes. Human 293T cells were transfected with
plasmids expressing GFP-Nup98 or GFP. 48 h after transfection, cells were lysed
and incubated at room temperature for 1 h with in vitro assembled wild type (A)
or N74D (B) HIV-1 CA–NC complexes. The mixtures were applied to a 70% sucrose
cushion and centrifuged. INPUT represents the lysates analyzed by Western
blotting before being applied to the 70% cushion. The input mixtures were
Western blotted using anti-GFP antibodies. Similarly, the pellets from the 70%
cushion (BOUND) were analyzed by Western blotting using anti-GFP and anti-p24
antibodies. The results of three independent experiments were similar; the result
of a single experiment is shown. Binding of Nup98 to HIV-1 CA–NC complexes
bearing the N74D change was quantiﬁed and normalized to the binding ability of
Nup98 to the wild type HIV-1 CA–NC complexes (% of GFP-Nup98 BOUND).
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complexes (Fig. 4A). As control, we found that GFP alone does
not interact with in vitro assembled HIV-1 CA–NC complexes
(Fig. 4A). Because HIV-1 bearing the capsid mutation N74D
overcomes the requirement for Nup98, we tested the ability of
Nup98 to interact with in vitro assembled HIV-1 CA–NC com-
plexes bearing the capsid change N74D. Nup98 bound HIV-1 CA–
NC complexes bearing the capsid change N74D with decreased
afﬁnity (2 fold) when compared to wild type CA–NC complexes
(Fig. 4B). These experiments demonstrated the ability of Nup98 to
interact with in vitro assembled HIV-1 CA–NC complexes. In
addition, the decreased binding of Nup98 to CA–NC complexes
bearing the capsid change N74D might explain in part the reason
that HIV-1–N74D infection is independent of Nup98.
Similarly, we tested the ability of Nup153 to interact with
in vitro assembled HIV-1 CA–NC complexes. As a positive control,
we included the capsid binder GFP–TRIM5arh (Fig. 5A). Similarly,
we found that GFP alone does not interact with in vitro assembled
HIV-1 CA–NC complexes (Fig. 5A). In agreement with our infec-
tivity data, we found that GFP-Nup153 binds HIV-1 CA–NC
complexes bearing the N74D as strong as the wild type HIV-1
CA–NC complexes (Fig. 5B). These results suggested that Nup153
binds the HIV-1 core during the early stages of infection.
Role of Nup98 and Nup153 in integration site distribution.
Depletion of nucleopore components or karyopherins modiﬁes
the integration targeting and reduces the integration efﬁciency of
HIV-1 (Di Nunzio et al., 2012; Konig et al., 2008; Ocwieja et al.,
2011); therefore, we hypothesized that depletion of Nup98 and
Nup153 may affect HIV-1 integration preferences and efﬁciency.
Having conﬁrmed that knockdown of Nup98 and Nup153 in
lymphocytes reduced the efﬁciency of infection, we examined
the role of these factors on integration site selection by preparing
integration site libraries using ligation-mediated PCR (LM–PCR),
as previously described (Cattoglio et al., 2010). To test this
hypothesis, we analyzed integration sites distribution in Nup98
and Nup153 -depleted Jurkat cells. For this purpose, we chal-
lenged Nup98 and Nup153 -depleted cells with a single-round
HIV-1 expressing the cell surface protein heat-stable antigen
(HIV-1-HSA) as a reporter of infection (Fig. 6A). As a control, we
challenged Jurkat control cells, which contain the shRNA empty
vector, with HIV-1-HSA. To isolate HIV-1HSA integration sites, we
digested the genomic DNA isolated from double positive cells for
GFP and HSA and ligated the digested products to DNA-linkers
(Fig. 6B). We ampliﬁed the integration sites by nested PCR using
as a template the ligated DNA (Fig. 6B) and sequenced the
fragments by 454-pyrosequencing (Cattoglio et al., 2010; Wang
et al., 2009). Primers annealing to the HIV-1 U3 region, which is
absent in shRNA expressing self-inactivated (DU3) lentiviral
vectors, were used to selectively amplify HIV-1-HSA integration
sites (Fig. 6B and Fig. S2). A total of 798, 1518 and 893 insertion
sites were mapped to the human genome (UCSC release hg19) in
control, Nup98- and Nup153-depleted Jurkat cells, respectively
(Fig. 6C). All UCSC known genes having their transcription start
site (TSS) at 750 kb from the annotated integration target.
Integrations were annotated as TSS-proximal when mapping in
a 72.5 kb interval around a TSS of known genes; intragenic when
occurring inside the transcribed portion of a known Gene (exons
and introns) 42.5 kb downstream of a TSS; and intergenic in all
the other cases (upstream or downstream of known genes)
(Cattoglio et al., 2010). Our results showed that Nup98 and
Nup153 -depleted cells exhibit a 5% and 8% decrease of integra-
tions occurring in intragenic sites, respectively, when compared
to Jurkat control cells (Fig. 6C and Table 1). In parallel, depletion
of Nup153 increased HIV-1 integration frequency in intergenicregions (Fig. 6C and Table 1). Nup98-depleted cells also showed a
modest increase (2%) in the proportion of intergenic HIV-1
integrations and a 2.7 fold increase in integrations occurring
in close proximity to TSSs. Finally, to evaluate the frequency of
Fig. 5. Binding of GFP-Nup153 proteins to in vitro assembled HIV-1 capsid-
nucleocapsid (CA–NC) complexes. Human 293T cells were transfected with
plasmids expressing GFP-Nup153, GFP–TRIM5arh or GFP. 48 h after transfection,
cells were lysed and incubated at room temperature for 1 h with in vitro
assembled wild type (A) or N74D (B) HIV-1 CA–NC complexes. The mixtures were
applied to a 70% sucrose cushion and centrifuged. INPUT represents the lysates
analyzed by Western blotting before being applied to the 70% cushion. The input
mixtures were Western blotted using anti-GFP antibodies. Similarly, the pellets
from the 70% cushion (BOUND) were analyzed by Western blotting using anti-GFP
and anti-p24 antibodies. The results of three independent experiments were
similar; the result of a single experiment is shown. Binding of Nup153 to HIV-1
CA–NC complexes bearing the N74D change was quantiﬁed and normalized to the
binding ability of Nup153 to the wild type HIV-1 CA–NC complexes (% of GFP-
Nup153 BOUND).
Fig. 6. Contribution of Nup98 and Nup153 to HIV-1 selection of integration sites.
(A) To measure HIV-1 infectivity Jurkat Nup98 and Nup153KD depleted cells were
infected with HIV-1-HSA and analyzed by Flow cytometry. As a control, we
challenged Jurkat control cells, which contain the shRNA empty vector, with HIV-
1-HSA. The graphic shows the % of HSA positive cells 3 days post-infection, these
cells were sorted by HSA beads before to start LM–PCR. (B) Strategy employed to
detect exclusively HIV-1-HSA and not the shRNA lentiviral vector, containing the
deletion in the U3 region of LTR, used to achieve knockdown cells. (C) Distribution
of HIV-1 integration sites in the genome of control, Nup98KD, Nup153KD Jurkat
cells. USCS known genes having their TSS in a 750 kb window around the
integration sites (798, 1518 and 893 for control, Nup98KD, Nup153KD Jurkat cells,
respectively) and a dataset of control 40,000 random sites were annotated.
Integrations were distributed inside (intragenic), outside (intergenic), or in the
promoter region (TSS-proximal) of UCSC known genes. Statistical differences
between the integration frequencies in Nup98 KD, Nup153 KD and control Jurkat
cells were determined by using a 2-sample test for equality of proportions
(*Po0.05; **Po0.005 and ***Po0.001).
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in Nup98- and Nup153-depleted cells, we measured the propor-
tion of integrations occurring in regions containing these genomicfeatures, which are hallmarks for open chromatin, by using online
available data sets (UCSC track containing annotated CpG islands
and ENCODE Jurkat DNase I hypersensitive sites; Fig. S3). Inter-
estingly, Nup153-depleted cells exhibited a reduced fraction of
integrations mapping to regions enriched in CpG islands and
DNaseI hypersensitive sites (Fig. S3).
Overall, these experiments suggested that Nup98 and Nup153
depletion reduces HIV-1 integration preferences for chromosomal
regions rich in genes and associated features such as CpG islands,
Table 1
Integration site distribution for Nup153 and Nup98 depleted cells.
Genomic features Jurkat control Jurkat Nup98KD Jurkat Nup153KD Random
n¼798 n¼1518 n¼893 n¼40,000
% Intragenic integrations (750 kb) 77.0 72.0 69.0 38.0
% Intergenic integrations (750 kb) 21.0 23.0 28.0 59.0
% TSS-proximal integrations (750 kb) 1.7 4.5 3.0 3.0
% Integrations on CpG islands (750 kb) 67.5 69.4 63.7 38.7
% Integrations in DNaseI hypersensitive sites (750 kb) 97.9 97.1 95.7 83.1
Gene density / integration (750 kb) 2.0 2.2 1.9 0.9
Average genes in 1 Mb 46.0 47.0 44.0 30.0
The table indicates the percentage of HIV integrations occurring in intragenic, intergenic, transcriptional start site (TSS)-proximal regions, and in close proximity to CpG
islands and in DNaseI hypersensitive sites. Computer-generated random control sequences were obtained from Cattoglio et al.( 2010).
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Nup153 inﬂuence HIV-1 integration in transcriptional units and
in regions characterized by an open chromatin conﬁguration, as
shown for other factors such as TNPO3 and RanBP2 (Ocwieja
et al., 2011; Schaller et al., 2011).
We corroborated these studies by doing a second infection and
sequencing more than 3000 proviral integration sites (Fig. S4).Discussion
To study the role of Nup153 and Nup98 in HIV-1-infection, we
depleted its expression in human Jurkat cells and study HIV-1
nuclear import and integration. These experiments conﬁrmed in
Jurkat cells the observation made in HeLa cells that depletion of
Nup153 mainly affects nuclear import while the depletion of
Nup98 slightly reduce HIV-1 integration (Fig. 1) (Di Nunzio et al.,
2012; Matreyek and Engelman, 2011). Our results suggested that
Nup153 play an important role on the nuclear import of HIV-1,
which is in agreement with the localization of Nup153 to the
nuclear basket region of the nucleopore with the C-terminal
domain exposed to the cytoplasmic face of the nucleopore
complex, possibly to enhance the nuclear transport activity (Ball
and Ullman, 2005; Paulillo et al., 2005, 2006). Similarly, we
studied the role of Nup98 in HIV-1 infection. Our ﬁndings indicate
that the 2-fold decrease on infectivity caused by Nup98 depletion
is due to an effect on the integration process, since HIV-1 nuclear
import seems not to be affected by depletion of Nup98. Interest-
ingly, we observed that the Nup98 depleted cells showed a an
increase of 2.7 fold for integration in transcriptional start sites
(TSS) respect to control cells. This observation is in agreement
with previous works in which Nup98 has been found to interact
with active genes, preferentially far away from the promoter
(Capelson et al., 2010; Kalverda and Fornerod, 2010).
Previous studies have suggested that the interaction of HIV-1
integrase with Nup153 is required for the nuclear import of HIV-1;
this work showed a direct interaction between the C-terminal
region of Nup153 and the integrase of HIV-1 with both proteins
produced in bacteria (Woodward et al., 2009). To explore this
interaction in proteins expressed in mammalian cells, we tested
the ability of full-length Nup153 to interact with HIV-1 integrase
using proteins produced in human 293T cells. Our results showed
that Nup153 was not able to interact with HIV-1 integrase at any of
the tested salt concentrations (Fig. 3). To test that our assay is
sensitive to bona ﬁde interactor of HIV-1 integrase, we showed the
previously described interaction of HIV-1 integrase with LEDGF/
p75 (Cherepanov et al., 2003). We believe that the difference
in results resides on the source of the proteins used to test
the interaction, bacteria versus mammalian cells. Our results
suggested that Nup153 does not interact with HIV-1 integrase in
mammalian cells.Genetic studies have suggested that capsid is the viral deter-
minant for the requirement of Nup153 (Matreyek and Engelman,
2011). To explore this possibility, we tested the ability of Nup153
to bind in vitro assembled HIV-1 CA–NC complexes, which
recapitulates the surface of the viral core (Pornillos et al., 2010).
This capsid binding assay has been extensively used to character-
ize the binding of TRIM5arh variants to capsid (Diaz-Griffero et al.,
2009; Lienlaf et al., 2011), among other capsid interactors such as
RANBP2, CPSF6 and TNPO3 (Di Nunzio et al., 2012; Lee et al.,
2010; Valle-Casuso et al., 2012). In agreement with the genetic
studies performed by Matreyek and colleagues, we found that
Nup153 binds in vitro assembled HIV-1 CA–NC complexes. This
result suggested that the interaction of Nup153 with the HIV-1
core might be important for the ability of HIV-1 to enter the
nucleus. Even thought our ﬁndings indicate that Nup98 is not
required for nuclear import, it binds HIV-1 CA–NC complexes,
which is a puzzling observation. Because Nup153 and Nup98
have in common the presence of phenylalanine–glycine (FxG)
repeats, one possibility is that the FxG repeats are directly
mediating the interaction of nucleoporins with in vitro
assembled HIV-1 CA–NC complexes (Matreyek oral communi-
cation CSH 2012). In agreement, we have previously shown the
binding of HIV cores by Nup358/RanBP2, which is a nucleoporin
that contains several FxG repeats (Di Nunzio et al., 2012).
Future analysis of the ability of different nucleoporins to bind
the HIV-1 core will establish whether FxG repeats are directly
involved in the ability of nucleoporins to interact with the
HIV-1 core.
Our ﬁndings indicate that Nup153 is involved in nuclear
import; however, the discrepancy found when comparing infec-
tivity with integration in Nup153-depleted cells suggested that
Nup153 might be also involved in integration (Fig. 1). Because the
decrease in infectivity observed in Nup153-depleted cells did not
directly correlate to a decrease in integration efﬁciency, we
hypothesized that HIV-1 in Nup153-depleted cells is integrating
in transcriptionally inactive regions. In agreement with our
hypothesis, our ﬁndings showed that Nup153-depleted cells
exhibit a 10% decrease in intragenic integrations (regions that
are likely to be transcriptionally active), which could in part
explain the discrepancy between HIV-1 infectivity and integration
in Nup153 depleted cells. In agreement, a recently published
report showed that depletion of Nup153 from HeLa cells
decreases the ability of HIV-1 to integrate in transcriptionally
active regions (Koh et al., 2012). The large phenotype observed
for HIV-1 infectivity in Nup153 KD cells suggested that Nup153
could be simultaneously affecting HIV-1 nuclear import and
integration. The functional duality of Nup153 could be occur-
ring by a direct or an indirect mechanism. A direct mechanism
implies that Nup153 interaction with HIV-1 is modulating
nuclear import and integration. An indirect mechanism, more
likely, will suggest that depletion of Nup153 interfere with the
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Mackay et al., 2009), which could result in the disruption of
HIV-1 infection at multiple stages. Future investigations will
explain whether the interaction between capsid and Nup153 is
functional for the virus.
Although Nup98 and Nup153 are involved in integration, the
mechanism by which this process occurs is not known. One
possibility is that the Nups target the PIC to speciﬁc regions of
the chromatin allowing preferential integration. A second
possibility will suggest that the Nups are rearranging the
chromatin conformation increasing the ability of HIV-1 to
integrate in transcriptionally active genes. Future experiments
will provide insights on how Nucleoporins facilitate HIV-1
integration.
Overall our work suggests that the defect on infectivity
observed for Nup153-depleted cells is due to the contribution of
Nup153 to nuclear import and integration, suggesting a link
between these two steps. We also demonstrated the ability of
Nup153 to bind the HIV-1 core suggesting that this interaction
might be required for nuclear import of HIV-1.Material and methods
Cells, lentiviral vector carrying shRNA and virus production
The Jurkat cells are CD4þ human T cells. The 293T cells are
human embryonic kidney cells. The TRIP–GFP vector was used to
produce lentiviral particles expressing speciﬁc shRNAs against
Nup98 and Nup153. TRIP–GFP vector, which is DU3, contains the
cis-acting sequences required for formation of the central DNA
Flap, and encodes the green ﬂuorescent protein (GFP) under the
control of the CMV promoter to monitor transduction. shRNA
cassettes were inserted in the 30 U3 region of the vector plasmid
to avoid increasing vector size and to increase shRNA expression
in transduced cells, since the U3 region is duplicated during
reverse transcription (Di Nunzio et al., 2012). To insert the shRNA
cassette, a polylinker (MluI, ClaI, MscI, NheI, SalI, XhoI) was
inserted at the U3 BamHI restriction site. Complementary oligo-
nucleotides coding for shRNAs were annealed and cloned into
BglII/HindIII of pSUPER (OligoEngine Invitrogen) downstream of
the H1 promoter. The H1–shRNA was then inserted into ClaI/NheI
of the vector plasmid polylinker, upstream in respect to the
internal pol II marker gene segments. Lentiviral particles expres-
sing speciﬁc shRNAs were produced by transient transfection of
293T cells with the vector plasmid, encapsidation plasmid (Dp
8.74), and the VSV-G envelope expression plasmid. After collec-
tion of supernatants at 48 h post-transfection, lentiviral particles
expressing speciﬁc shRNAs were concentrated by ultracentriga-
tion for 1 h at 22,000 rpm at 4 1C and stored at 80 1C. Lentiviral
particles expressing speciﬁc shRNAs were titered in HeLa P4-CCR5
cells using ﬂow cytometry to assess GFP expression at 4 days
post-transduction.
Jurkat cells were transduced with Lentiviral particles expres-
sing speciﬁc shRNAs against Nup98 at MOI 50 and 100 and
LV-shRNA against Nup153 at MOI 30, 50, 70 and 100 to generate
stable knockdown cells.
HIV-1 viruses were produced by co-transfection of 293T cells
with NL4.3-IRES-HSA ENV or NLX Luc ENV and the Vesicular
Stomatitis Virus glycoprotein (VSV-G) envelope expression plas-
mid pHCMV-G (VSV-G). The viruses harvested from 293T cells
48 h post-transfection were treated with 25 U/mL of DnaseI
(Roche) and with 100 mM MgCl2 at 37 1C for 30 min. Viruses
normalization were performed by p24 ELISA according to the
manufacturer’s instructions (Perkin Elmer).Cell separation and LM–PCR
Twenty million of Jurkat cells were infected with 10 mg of p24
antigen of NL4.3-IRES-HSA ENV. Three days later, virus-infected
cells were sorted using the biotinylated anti-HSA antibody (clone
M1/69, BD Biosciences) used at a ﬁnal concentration of 3 mg/ml
for 30 min on ice followed by 15 min with beads anti biotin (BD).
After seven washes in PBS/0.5%BSA/2mMEDTA, a small fraction of
sorted cells was labelled with antibody PE- conjugated anti-HSA
rat (BD 532262) and analysed by ﬂow cytometry. Genomic DNA
was extracted by QIAamp DNA micro kit (QIAGEN) and digested
with the 4-cutter enzyme BfaI and BglII to prevent the ampliﬁca-
tion of internal 30 LTR fragments. A BfaI double-stranded linker
was then ligated, and viral 50LTR-genome junctions were ampli-
ﬁed by LM–PCR using primers speciﬁc for the linker and the 50
LTR of HIV-1 (primer linker: 50 AGGGCTCCGCTTAAGGGAC 30;
primer HIV-1 50 LTR: 50 TGGTAGATCCACAGATCAAGGA 30). HIV-1
50 LTR primer anneals to the U3 region of 50LTR present only in
NL4.3-IRES-HSA ENV- after viral integration and absent in Trip
self-inactivated LV-shRNA (Fig. S2). A further PCR step was
performed to include sample speciﬁc barcodes for parallel
sequencing using the 454/ Roche pyrosequencing platform as
previously described (Cartier et al., 2009; Cattoglio et al., 2007,
2010). Raw sequence reads were processed through an automated
bioinformatic pipeline that eliminated small and redundant
sequences and were mapped to the UCSC hg19 release of the
human genome (Cattoglio et al., 2010). Sequences with 90% or
greater identity to the human genome were considered genuine
integration sites. As control dataset, we used 40,000 random sites
from Cattoglio et al. (2010).
Genomic features (CpG islands and DNaseI hypersensitive
sites) were annotated when their genomic coordinates over-
lapped for at least 1 nucleotide with a 50-kb interval surrounding
each integration site. We used UCSC tracks for both cytosine–
phosphate–guanosine (CpG) islands and Jurkat DNaseI
hypersensitive sites.
Western blotting and co-Immunoprecipitation
Proteins were extracted on ice from control and KD cells using
RIPA buffer (20 mM HEPES p H 7.6, 150 mM NaCl, 1% sodium
deoxycholate, 1% Nonidet P-40, 0.1% SDS, 2 mM EDTA, complete
protease inhibitor [Roche Diagnostics]), and protein concentration
was quantiﬁed using the Dc Protein Assay (Bio-Rad Laboratories)
with bovine serum albumin as standard. 100 mg of total protein
lysate was loaded onto SDS–PAGE 6% Tris–glycine gel (Invitrogen)
for Nup153, and 20 mg onto 4–12% Bis-Tris gel (Invitrogen) for
Nup98. Revelation was carried out using the ECL Plus Western
Blotting kit (GE Healthcare). Primary antibodies used for Western
blotting (WB) were rat anti-Nup98 (AbcamWB 1:4,000, IF 1:100),
anti-mouse Nup153 (SA1, kind gift from B. Burke, WB 1:500, IF
1:10). Secondary or conjugated antibodies used for Western
blotting were Beta Actin HRP conjugated antibody (Abcam,
1:2,500), anti-mouse IgG HRP (GE Healthcare, 1:5,000), anti-
rabbit IgG HRP (GE Healthcare, 1:5,000),anti-rat IgG HRP (Sigma,
1:80,000), and LEDGF/P75 (Bethyl Laboratories, Inc. cat. A300-
847A). Human 293T cells were co-transfected with different HIV-
1 integrase containing a FLAG epitope tag on the C-terminus,
LEDGF/p75-HA tag, pGFP-Nup98 and pGFP-Nup153 (kindly gift by
Dr. Jan Ellenberg). Transfected cells were lysed in extraction
buffer [0.5% Triton X-100, 50 mM Tris–HCl, pH¼8, 2 mM MgCl2,
5% glycerol and protease inhibitors (Roche)] containing 100 mM,
200 mM or 300 mM NaCl as indicated. Extracts were pre-cleared
using protein-A agarose beads (Sigma) at 4 1C for 1 h. Integrase
proteins were immunoprecipitated using agarose beads linked to
anti-FLAG antibodies (Sigma). Beads were washed 3 times, and
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sample buffer. Samples were then analyzed by Western blotting
using antibodies against FLAG (Sigma), antibody anti-HA
(Covance MMS-101R) and antibody anti-GFP (Clontech 632459).HIV-1 CA–NC expression and puriﬁcation
The HIV-1 CA–NC protein was expressed, puriﬁed and
assembled as previously described (Ganser et al., 1999). The
pET11a expression vector (Novagen) expressing the CA–NC pro-
tein of HIV-1 was used to transform BL-21(DE3) E. coli. CA–NC
expression was induced with 1 mM isopropyl-b-D-thiogalactopyr-
anoside (IPTG) when the culture reached an optical density of
0.6 at 600 nm. After 4 h of induction, the cells were harvested and
resuspended in 20 mM Tris–HCl (pH 7.5), 1 mM ZnCl2, 10 mM
2-mercaptoethanol and protease inhibitors (Roche). Lysis was
performed by sonication, and debris were pelleted for 30 min at
35,000 g. Nucleic acids were stripped from the solution by using
0.11 equivalents of 2 M (NH4)2SO4 and the same volume of 10%
polyethylenimine. Nucleic acids were removed by stirring and
centrifugation at 29,500 g for 15 min. The protein was recovered
by addition of 0.35 equivalents of saturated (NH4)2SO4. The
protein was centrifuged at 9820 g for 15 min and resuspended
in 100 mM NaCl, 20 mM Tris–HCl (pH 7.5), 1 mM ZnCl2 and
10 mM 2-mercaptoethanol. Lastly the CA–NC protein was dia-
lyzed against 50 mM NaCl, 20 mM Tris–HCl (pH 7.5), 1 mM ZnCl2
and 10 mM 2-mercaptoethanol, and stored at 80 1C.In vitro assembly of CA–NC complexes
HIV-1 CA–NC particles were assembled in vitro by diluting the
CA–NC protein to a concentration of 0.3 mM in 50 mM Tris–HCl
(pH 8.0), 0.5 M NaCl and 2 mg/ml DNA oligo-(TG)50. The mixture
was incubated at 4 1C overnight and centrifuged at 8600 g for
5 min. The pellet was resuspended in assembly buffer (50 mM
Tris–HCl (pH 8.0), 0.5 M NaCl) at a ﬁnal protein concentration of
0.15 mM (Ganser-Pornillos et al., 2004; Ganser et al., 1999), and
stored at 4 1C until needed.Binding of Nup98 and Nup153 to HIV-1 capsid complexes
293T cells were transfected with plasmids expressing GFP-
Nup98, GFP-Nup153, GFP-TRIM5arh, GFP proteins. 48 h after
transfection, cell lysates were prepared as follows: washed cells
were resuspended in capsid-binding buffer (10 mM Tris, pH 7.4,
1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT). The cell suspension was
frozen and thawed, and incubated on ice for 10 min. Next, the
lysate was centrifuged in a refrigerated Eppendorf microcentri-
fuge (14,000 g) for 5 min. The supernatant was supplemented
with 1/10 volume of 10 PBS and then used in the binding assay.
To test binding, 5 ml of CA–NC particles assembled in vitro were
incubated with 200 ml of cell lysate at room temperature for 1 h. A
portion of this mixture, henceforth referred to as ‘‘INPUT’’ was
stored. The mixture was spun through a 70% sucrose cushion (70%
sucrose, 1 PBS and 0.5 mM DTT) at 100,000 g in an SW55
rotor (Beckman) for 1 h at 4 1C. After centrifugation, the super-
natant was carefully removed and the pellet was resuspended in
1 SDS–PAGE loading buffer and henceforth referred to as
‘‘BOUND.’’ The level of GFP-fusion proteins was determined by
Western blotting with an anti-GFP antibody as described above.
The level of HIV-1 CA–NC protein in the pellet was assessed by
Western blotting with an anti-p24 capsid antibody.Luciferase assays
Luciferase (Promega) activity was measured 48 h p.i according
to manufacturer’s instructions, using a microplate ﬂuorimeter
(Victor, Perkin Elmer). Protein quantiﬁcation by Bio-Rad protein
assay was carried out on the same lysates to normalize the
luciferase data for protein content.Quantitative PCR
Infected cells and control infected cells cultured in the pre-
sence of 5 mM nevirapine were treated for 30 min at 37 1C with
1000 U of DnaseI (Roche). Total cellular DNA was then isolated
using the QIAamp DNA micro kit (QIAGEN). Two long terminal
repeat (2-LTR) containing circles were detected using primers
MH535/536 and probe MH603 (Butler et al., 2001), using as
standard curve the pUC2LTR plasmid, which contains the HIV-1
2-LTR junction. Assessment of integration by Alu-PCR was per-
formed as previously described (Brussel and Sonigo, 2003).
To rule out ampliﬁcation of LV-shRNA, the 50 primer used for
the ﬁrst ampliﬁcation step was designed to recognize a unique
sequence in HIV-1 U3 not present in LV–shRNA. As inBrussel and
Sonigo (2003) this primer was extended with the lambda phage-
speciﬁc heel sequence shown in bold (50-atgccacgtaagc-
gaaactttccgctggggactttccaggg). The U3 modiﬁed primer was used
in combination with two Alu primers (50-tcccagctactggggaggct-
gagg) and (50-gcctcccaaagtgctgggattacag). DNA generated from
WT-infected cells was endpoint diluted in DNA prepared from
uninfected cells to generate the integration standard curve and
serial dilutions were made starting from 50,000 infected cells.
Each sample ampliﬁed contained 104 infected cells mixed at
40,000 uninfected cells. The control of the ﬁrst round PCR was
the ampliﬁcation without Alu primers using rTth DNA polymerase
XL as recommended by the manufacturer (Applied Biosystems
Inc, Foster City, CA N808-0187). Dilution 1:10 of the ﬁrst round
was ampliﬁed using the phage lambda Spa primer (50-atgccacg-
taagcgaaact) and U5-speciﬁc primer (50- ctgactaaaagggtctgagg)
with the probe (6FAM- ttaagcctcaataaagcttgccttgagtgc-TAMRA).
Both 2-LTR and Alu-PCR reactions were carried out at 24 h p.i and
normalized by ampliﬁcation of the housekeeping gene b-Actin
using the following primers and probe (50-aacaccccagccatgtacgt),
(50-cggtgaggatcttcatgaggtagt), (6FAM-ccagccaggtccagacgcagga-
BBQ). Reactions contained 1X FastStart Universal Probe Master
Mix (Rox) 2X (Roche), 300 nM forward primer, 300 nM reverse
primer, 100 nM probe primer and template DNA in a 20 ml
volume. After initial annealing (50 1C for 2 min) and denaturation
steps (95 1C for 15 min), 40 cycles of ampliﬁcation were carried
out (95 1C for 15 s, 58 1C for 30sec, and 72 1C for 30 s). As a
control, single cycle Luciferase activity assays were systematically
carried out to certify the phenotype.Acknowledgments
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